Hossein Borghaei, DO

The Phase 3 IMforte trial demonstrated that maintenance therapy with lurbinectedin plus atezolizumab was well tolerated and explored a novel approach to extending disease control following first-line treatment in patients with extensive-stage small cell lung cancer.

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.

Hossein Borghaei, DO, MS, discusses the investigation of nivolumab plus ipilimumab and chemotherapy in patients with metastatic non–small cell lung cancer.

Hossein Borghaei, DO, MS; and Martin Reck, MD, PhD, discuss factors that affect treatment selection in NSCLC, and the role of molecular and biomarker testing.

Hossein Borghaei, DO, MS, discusses unique characteristics of EGFR exon 20 insertion mutations in non–small cell lung cancer.

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the PACIFIC trial in patients with non–small cell lung cancer (NSCLC).

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the management of slightly rarer side effects that patients with lung cancer can experience when treated with immunotherapy agents.

Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab (Keytruda) in second-line non–small cell lung cancer (NSCLC).

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).